Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Happel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 3.47
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 8.01
Financials
Revenue
$0.00-100.0%Net Income
$-19.15MEBITDA
$-19.15MFree Cash Flow
$-12.11MEPS (diluted)
$-0.31Shares Outstanding (diluted)
62.34M+181.1%Operating Expenses
$21.57MCash & Debt
$236.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-51.04M | $-1.58 |
| 2024 | $0.00 | $-45.57M | $-1.45 |
| 2023 | $2.00M | $-27.88M | $-1.53 |
| 2022 | $0.00 | $-30.50M | $-1.38 |
| 2021 | $0.00 | $-24.44M | $-1.10 |
| 2020 | $0.00 | $-11.37M | $-0.51 |
| 2019 | $0.00 | $-14.26M | $-0.64 |
Valuation
SGMThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-9.09%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·10d ago·Neutral
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates FOSTER CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today reported financial results for the quarter ended September 30, 2026, and provided corporate updates.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
…ication Exercise, Not A Discovery Bet Sagimet Biosciences pivots denifanstat to acne, with robust Phase 3 data and a fully funded U.S. registrational trial underway. SGMT trades below cash value, presenting an asymmetric risk/reward profile as the main risk is U.S. data replication, not drug discovery. Denifanstat's efficacy and tolerability profile positions it as a differentiated oral acne therapy, targeting sebum production with potential for chronic use.
View source ↗ - Newszacks.com·38d ago·Negative
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·44d ago·Positive
… 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the positive 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license par…
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
…ng of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
…lion Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares o…
View source ↗ - Newsglobenewswire.com·53d ago·Positive
… 2026 Sagimet to host a KOL event and webcast September 30, 2026 at 1 PM ET FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioSci…
View source ↗ - Newsglobenewswire.com·81d ago·Positive
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
…ed to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.
View source ↗ - Newsmarketbeat.com·97d ago·Neutral
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
View source ↗
Earnings
Wed, Mar 10(in 4 months)
Consensus estimate $-0.33 per share
Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.31 vs $-0.26miss
- Tue, Aug 11$-0.26 vs $-0.25miss
- Tue, May 12$-0.33 vs $-0.39beat
- Wed, Mar 11$-0.29 vs $-0.43beat
- Thu, Nov 13$-0.40 vs $-0.41beat
- Wed, Aug 13$-0.32 vs $-0.52beat
Estimates and results for SGMT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SGMT officers and directors.
- Bought
- $544k
- Sold
- $5.9m
2 trades
18 trades
- Kemble Georgesold
- Kemble Georgesold
- Happel Davidsold
- Rozek Elizabethsold
- Kemble Georgesold
- Happel Davidsold
- Chauche Thierrysold
- Martins Eduardo Brunosold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SGMT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
